Full Press Release Details
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET
CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.
Citius Chairman and CEO, Leonard Mazur , will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related bloodstream infections. A question and answer period will follow management's discussion.
Conference Call Details:
Date:
Monday, June 3, 2024
Time:
8:30 a.m. Eastern Time 1-866-777-2509 (U.S. toll free)
Dial In:
1-412-317-5413 (international)
Webcast:
Register for the webcast here . A replay will be available on the Citius website ( www.citiuspharma.com ) for 90 days following the event.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok ® and LYMPHIR™. In May 2024 , Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com .
Investor Contact:
Ilanit Allen [email protected] 908-967-6677 x113
Media Contact:
STiR-communications Greg Salsburg [email protected]